CUMYL-CB-MEGACLONE
CUMYL-CB-MEGACLONE (CUMYL-CBMGACLONE, SGT-273) is a gamma-carboline based synthetic cannabinoid receptor agonist that has been sold as a designer drug, first being identified in Hungary in April 2020.[1]
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
IUPAC name
| |
| Chemical and physical data | |
| Formula | C25H26N2O |
| Molar mass | 370.496 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
See also
References
| Phytocannabinoids (comparison) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Endocannabinoids |
| ||||||||||||||||||||||||||||||||||||||||||||||||||
| Synthetic cannabinoid receptor agonists / neocannabinoids |
| ||||||||||||||||||||||||||||||||||||||||||||||||||
| Allosteric CBR ligands |
| ||||||||||||||||||||||||||||||||||||||||||||||||||
| Endocannabinoid enhancers (inactivation inhibitors) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||
| Anticannabinoids (antagonists/inverse agonists/antibodies) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| Receptor (ligands) |
| ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Transporter (modulators) |
| ||||||||||||
| Enzyme (modulators) |
| ||||||||||||
| Others |
| ||||||||||||
| |||||||||||||
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.